Education
About Us
Working with TipRanks
Follow Us
Tivic Health Systems (TIVC)
NASDAQ:TIVC
RESEARCH TOOLSreports
Top Page
Tivic Health Systems
(NASDAQ:TIVC)
45Neutral
Tivic Health Systems (TIVC) vs. S&P 500 (SPY)
Market Cap
$1.98M
Dividend YieldN/A
Average Volume (3M)1.24M
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth-22.00%
EPS Growth92.73%
CountryUS
Employees9
SectorHealthcare
Sector Strength78
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-52.46
Shares Outstanding612,536
10 Day Avg. Volume72,306
30 Day Avg. Volume1,242,530
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.88
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Tivic Health Systems Business Overview & Revenue Model
Company DescriptionTivic Health Systems Inc is a commercial stage bioelectronic medicine company focused on treating diseases and conditions by modulating the electrical signals carried along various nerve pathways. It focus on non-invasive products that offer consumers choice in the treatment of inflammation and related conditions.
How the Company Makes MoneyTivic Health Systems generates revenue through the sale of its ClearUP Sinus Relief device. The company's primary revenue stream comes from direct-to-consumer sales through its online platform and partnerships with major retailers. Tivic Health also engages in strategic collaborations with healthcare providers to expand its market reach. Significant factors contributing to its earnings include consumer adoption of non-invasive, drug-free treatments and the growing demand for innovative medical technologies.
Tivic Health Systems Financial Statement Overview
Summary
Tivic Health Systems shows financial challenges with declining revenue and consistent net losses. Although the company maintains a strong equity position, profitability and cash flow remain significant concerns, impacting financial stability. Operational improvements are necessary to enhance margins and achieve sustainable growth.Income Statement
Tivic Health Systems shows declining revenue from 2022 to the TTM. The gross profit margin is low at 25.5% for TTM, and the company is operating at a significant net loss, with a net profit margin of -670.95%. EBIT and EBITDA margins are also negative, indicating operational inefficiencies. Revenue growth is negative from 2022 to the TTM, marking a concerning trend.28
Negative
Balance Sheet
The company maintains a strong equity position with a high equity ratio of 83.5% in TTM, indicating low leverage. There is no debt, resulting in a favorable debt-to-equity ratio. However, the return on equity is negative due to substantial net losses, highlighting a lack of profitability.55
Neutral
Cash Flow
Tivic Health Systems has negative free cash flow, although it has improved slightly in the TTM period. The operating cash flow to net income ratio is negative, underscoring cash flow challenges. The company is reliant on financing activities, as seen in positive financing cash flow, which may pose a risk if not managed appropriately.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 957.00K | 1.18M | 1.84M | 1.17M | 860.00K | 420.00K | Gross Profit |
| 244.00K | 287.00K | 299.00K | -129.00K | -225.00K | -289.00K | EBIT |
| -6.36M | -8.24M | -10.10M | -5.63M | -3.20M | -3.64M | EBITDA |
| -6.24M | -8.06M | -9.92M | -6.65M | -3.21M | -3.70M | Net Income Common Stockholders |
| -6.42M | -8.24M | -10.10M | -8.49M | -4.08M | -4.15M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.31M | 3.40M | 3.52M | 12.97M | 1.04M | 2.31M | Total Assets |
| 0.00 | 5.16M | 5.86M | 15.04M | 1.53M | 3.02M | Total Debt |
| 0.00 | 369.00K | 530.00K | 708.00K | 1.47M | 0.00 | Net Debt |
| 2.31M | -3.03M | -2.99M | -12.27M | 425.00K | -2.31M | Total Liabilities |
| 0.00 | 1.58M | 2.23M | 1.76M | 2.71M | 653.00K | Stockholders Equity |
| 2.37M | 3.58M | 3.63M | 13.27M | -1.18M | 2.37M |
| Cash Flow | Free Cash Flow | ||||
| -6.02M | -8.63M | -8.93M | -5.61M | -3.03M | -3.70M | Operating Cash Flow |
| -6.13M | -8.51M | -8.92M | -5.61M | -3.03M | -3.67M | Investing Cash Flow |
| 118.00K | -118.00K | -11.00K | 0.00 | 0.00 | -31.00K | Financing Cash Flow |
| 3.15M | 8.51M | -528.00K | 17.54M | 1.76M | 5.55M |
Tivic Health Systems Technical Analysis
Negative
3.41
Price Trends
5.52
Negative
5.12
Negative
5.56
Negative
Market Momentum
-0.75
Positive
34.70
Neutral
10.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIVC, the sentiment is Negative. The current price of 3.41 is below the 20-day moving average (MA) of 6.41, below the 50-day MA of 5.52, and below the 200-day MA of 5.56, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 34.70 is Neutral, neither overbought nor oversold. The STOCH value of 10.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TIVC.
Tivic Health Systems Risk Analysis
Tivic Health Systems disclosed 48 risk factors in its most recent earnings report. Tivic Health Systems reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tivic Health Systems Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $853.33M | ― | -913.07% | ― | 31.76% | 24.85% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
45 Neutral | $1.98M | ― | -149.34% | ― | -22.00% | 92.73% | |
44 Neutral | $139.71M | 163.08 | 111.75% | ― | 5.41% | ― | |
40 Underperform | $6.97M | ― | -499.57% | ― | 166.27% | ― | |
39 Underperform | $400.04M | ― | -166.29% | ― | 0.37% | -20.49% | |
38 Underperform | $4.26M | ― | -285.35% | ― | 674.14% | 89.05% |
* Healthcare Sector Average
Performance Comparison
TIVC
Tivic Health Systems
3.18
-17.73
-84.79%
SONN
Sonnet BioTherapeutics Holdings
1.32
-12.04
-90.12%
SENS
Senseonics Holdings
0.57
<0.01
1.79%
INSG
Inseego
9.09
6.30
225.81%
EOLS
Evolus
12.96
-1.11
-7.89%
PAVM
PAVmed
0.61
-1.47
-70.67%
Tivic Health Systems Earnings Call Summary
Earnings Call Date: Nov 15, 2024 | % Change Since: -45.35% | Next Earnings Date: Mar 21, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in operational efficiency and promising developments in the Vagus Nerve Stimulation program, albeit overshadowed by notable declines in revenue, sales, and cash position. The company's strategic focus on its VNS program and cost management efforts show potential for future growth, but current financial metrics indicate challenges.Highlights
ClearUP Product Line Improvements
Achieved over 70% gross margin on ClearUP sales post-restructuring, up from 40%-50% previously, and a significant improvement from a negative gross margin two years ago.
Cost Management Success
Operating expenses reduced to $1.5 million from $1.9 million last year, contributing to a 20% reduction in year-over-year net operating loss.
Vagus Nerve Stimulation Program Progress
Completed Phase I trial with industry-leading data, optimization study enrollment, and identified top use cases for the technology with the help of Fletcher State.
Financial Leadership Transition
Lisa Wolf joined as interim CFO, bringing over 30 years of financial leadership experience, including public and private finance.
Lowlights
Revenue and Sales Decline
Revenue net of returns decreased by $219,000 (27%) to $600,000 compared to a year ago. Unit sales decreased by 36%.
Gross Profit and Margin Decrease
Gross profit for the third quarter was $44,000, down from $108,000 a year ago. Gross margin decreased to 35% from 38% in 2023.
Cash Position Decline
Cash and cash equivalents totaled $2.2 million, down from $3.4 million at the end of 2023.
Company Guidance
During the Tivic Health Systems Q3 2024 earnings call, CEO Jennifer Ernst outlined the company's strategic focus on enhancing shareholder value through three main avenues. Firstly, the company aims to turn its ClearUP product line profitable, despite a 36% decrease in unit sales and a 27% revenue decline to $600,000 compared to the previous year. This was partially offset by a 13% increase in average sales price and improvements in gross margin, which reached 70% post-supply chain adjustments. Secondly, Tivic is advancing its noninvasive vagus nerve stimulation (VNS) program, having completed a Phase I trial and commenced a Phase I optimization study. The VNS market is projected to grow significantly, and Tivic has identified over 30 potential use cases for its VNS device. Finally, the company is focused on reducing operating expenses, achieving a 20% year-over-year reduction in net operating loss. Cash and cash equivalents stood at $2.2 million as of September 30, 2024, down from $3.4 million at the end of 2023, as the company navigates its strategic initiatives.Tivic Health Systems Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Tivic Health Systems Advances in VNS and ClearUP 2.0
Positive
Dec 23, 2024
Tivic Health Systems has shown notable advancements in its commercial business and its entry into the vagus nerve stimulation (VNS) sector. The company launched ClearUP 2.0, improved customer engagement, and enhanced its supply chain and marketing strategies, achieving significant growth in gross margins. Tivic is focusing on non-invasive VNS, which offers a substantial market opportunity, and has demonstrated promising results in pilot studies. The company is expanding its intellectual property portfolio and aims to move into clinical trials in 2025, expecting these developments to drive long-term shareholder value.
Private Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
Tivic Health Systems Advances in Bioelectronic Medicine
Positive
Nov 14, 2024
Tivic Health Systems reported its third quarter 2024 financial results, highlighting significant advancements in their bioelectronic medicine strategies. The company is making strides with its non-invasive vagus nerve stimulation system, aiming to break into high-value markets. Despite a drop in sales, Tivic has improved its product line profitability and reduced operational expenses, while also raising capital through stock sales. The company’s innovative approaches are setting the stage for future growth opportunities in the healthcare sector.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.